The Five GLP-1 Personas
When the pill costs twenty-five dollars and anyone can get it, what decides the future is not whether you take it. It is what the drug becomes to you, and there are five answers.
I write about this space wearing two hats. As a consumer, what I want first is simple: to cut through the clutter, to make sense of the wall of marketing and counter-marketing being thrown at all of us about these drugs. Then, as a builder, I want something else, to step back and synthesize, to take the scattered pieces of this thing and ask what they add up to: what it does to the industry, and what the future looks like, midterm and long. Being at the front of a changing tide rather than pulled under it comes down to reading the macro early and reading it right.
Plenty of people are mapping the secondary and tertiary effects of GLP-1s, and I think the lens is generally fine, but also too general. As mine sharpens, what comes into focus is not the drugs, it is the people and how they connect with the tool, and from there the infrastructure, the support, and the whole shape of the category follow. So this piece steps back to ask the question underneath the noise: what does consumption, and our relationship with these drugs, actually look like in the future world where we’ve solved both affordability and accessibility?
The trade that got faked out
In 2023, the smart money shorted snacks.
The logic looked clean. A drug had arrived that turns off hunger, the people taking it were buying less food, and if you ran that forward, the packaged-food giants were facing structural decline. The stocks sold off on it. Headlines wrote the obituary for the potato chip.
The mechanism was real. The most careful study we have, out of Cornell, found that within six months of starting a GLP-1 a household cuts grocery spending by about 5 percent, more than 8 percent in higher-income homes, with fast food and coffee down around 8 percent. The cuts land hardest exactly where you would expect, on the ultra-processed, calorie-dense, craving-driven food.
So why did the trade get faked out? Because of one detail the short missed. The spending cut holds for the people who stay on the drug. It reverses for the people who quit. In the Cornell data, roughly a third of users stopped during the study window, and their food spending climbed right back to where it started. The recovery everyone pointed to as proof the bears were wrong was not the drug failing to change behavior. It was a third of the users walking away from the drug.
That is the whole game hiding in a footnote. The snack short was never wrong about appetite. It was wrong, or early, about adherence. Its entire profit and loss rides on a single question: when these drugs are cheap and everywhere, do people stay on them?
Here is the part I keep coming back to. If everyone stays on, the snack short is eventually right, and the demand destruction is permanent. If everyone cycles on and off, the short is wrong, and what food companies face is not a decline but a choppy, fluctuating demand pattern they have to learn to ride. The trade is not a bet on the drug. It is a bet on human behavior. And human behavior here does not have one answer. It has five.
The wave is already here
This did not creep up on us. It went mainstream earlier this year the way things do now, through people we recognize, when public figures led by Serena Williams started talking openly about being on a GLP-1. Fronting a Super Bowl campaign for the telehealth company Ro, Williams framed it as biology over willpower, science over vanity, and that did more to normalize these drugs than any clinical trial could.
But culture is not a market. Supply and price are. The first oral GLP-1 for weight loss, the Wegovy pill, launched on January 5 and became one of the strongest drug launches in US history by volume: three million prescriptions in just over five months, more than 80 percent of them to people who had never been on a GLP-1 before. It is not stealing patients from the injection, it is pulling in millions who were never in the room. Eli Lilly’s Foundayo followed in the spring, a non-peptide small molecule cheap enough to manufacture at scale, which is what makes durable mass pricing real. Copays are already reaching twenty-five dollars, the pipeline behind them runs deep, and a drug that was a niche is on its way to a third of the country. Which makes now the right time to think beyond pipeline and cost, to a future state (likely not that far out), when everyone has easy, cheap access. Then, the interesting question is not whether it works, but who all these people are, and what their relationship with the drug becomes.
Not one future. One question.
I see two lazy takes about where this goes.
The first is that cheap and oral turns GLP-1s into a casual lifestyle product. On for a wedding, off for the summer, treated like a juice cleanse with a prescription.
The second is the opposite, that it turns everyone into a statin patient, quietly medicated for life, the way an earlier generation absorbed cholesterol pills into the daily routine and stopped thinking about it.
Both are real outcomes. Neither is the outcome, because they describe different people. And the thing that sorts those people is not willpower, and it is not even how their body handles the drug. It is a simpler question, the one I think the whole market is about to organize itself around: what is this drug to you? What job does it do in your life? Because that role, far more than your dose, or how long you have been on, or how loudly you talk about it, is what predicts how you behave and what you will buy.
One thing does sit upstream of the question, and it is worth acknowledging: whether your body can take the drug at all. Some people cannot. The side effects end it before any of the rest applies, and they become a type of their own. It also creates a selection effect nobody prices in: the people you see using these drugs gracefully are disproportionately the ones who tolerate them well. Everyone who got hammered washed out before the story started.
Everything else, the dose, the secrecy, whether you are on right now or between rounds, is a layer, not a type. A person can run loud or quiet, full dose or a sliver, and still be the exact same kind of customer. So answer the one question, what is the drug to you, and you do not get a future. You get five personas that will crave different infrastructure to support their new relationship with a drug that affects multiple areas of their life.
The five personas
Picture the next decade as a room with five people in it. They can be on the identical molecule and be completely different customers, because each one has hired the drug to do a different job.
The Lifeline. To this person the drug is medicine. They came to it through a doctor, for something that genuinely matters to their long-term health: diabetes, a heart or metabolic risk, weight that had crossed from cosmetic into clinical. It is treatment, not a tweak. For the Lifeline this is simply a medicine they will take for the long haul, the way a person takes a blood-pressure pill, because their health is measurably better with it than without it.
The Staple. To this person the drug is a staple. Maybe they started for a proactive-medical reason or to lose weight, felt the benefits ripple out beyond the scale, and now it is just part of how they live, folded in like a daily vitamin. Whether they take a full dose or a sliver, whether they announce it at dinner or never bring it up, does not change what they are: someone who tried it, liked the life it gave them, and is not giving that up. It is mostly elective, so today they pay out of pocket or work to get it covered, and they will keep finding a way, because to them this is not treatment, it is just better living.
The Cycler. To this person the drug is a tool. They are not treating a condition, they are reaching for a goal. They use it in deliberate stretches, hit the target, step off, and pick it back up when they decide to. They are the one holding the on-off switch. The open question hanging over the Cycler, the one the science still has not answered, is whether deliberate on-and-off use holds the result over years. They are running that experiment in real time.
The Longevity Optimizer. To this person the drug is an upgrade. Not heavy, not sick, they run a GLP-1 for what sits underneath: the metabolic markers, the inflammation, the long bet on healthspan. One input in a stack they are forever tuning. They are the newest face in the room and the least studied in this particular use, which is worth a note rather than an alarm. For the Optimizer this was never about sickness, or even weight. It is engineering wellness.
The Locked Out. To this person the drug is a closed door, and it is not their fault. For some, the body refused it and the side effects made it unlivable. For others, the door was money, the coverage that lapsed or the price that spiked, and they came off a cliff they never chose to jump from. Either way the benefits are real and sitting right there, just out of reach. This is the most sympathetic person in the set, and the one the next few years are built to rescue: as the pill gets cheap and reliable and the gentler molecules arrive, the door that was shut starts to open. The Locked Out is not a failure. They are a waiting list the future will hopefully clear.
The caveat
A reminder: I am by no means a doctor. Everything above is speculation and hypothesis, built from how I see this space and from listening, closely, to a lot of people living it. And for the record, I am card-carrying Staple community myself, so read all of this as one person’s view, not a verdict.
When I say tens of millions may stay on these for life, that is me hypothesizing a path, not calling a certainty, and it is a path none of us has watched all the way down. Statins earned their permanent spot in the daily pillbox over more than thirty years of evidence; lifelong GLP-1 use, in young and basically healthy people mostly chasing a number, is about three years old. The ancillary benefits piling up in the research, the heart, the kidneys, maybe more, look real and encouraging. But no problems so far is not a track record when the so-far is this short. Call my posture toward the statinification story conviction with an asterisk, and the asterisk reads: pure hypothesis.
Why the personas are the whole point
Most GLP-1 commentary is chasing a number: how big, how fast, how much demand destroyed, how much value created. The thing that matters is not the number. It is a set of relationships, the ones people form with this miracle of a drug, and what it becomes to each of them. That is what decides how they behave, what they buy, and how much of their wallet flows into the drug and the entire economy of products and tools growing up around it.
Which is why, if you are trying to build rather than narrate, the segmentation is the asset. Each of these five is asking for something different, and almost none of it exists yet.
The Lifeline needs what any chronic patient needs: reliable, covered, forever supply, and the clinical infrastructure around a medicine you take for life. The Staple needs it to stay easy, affordable, and socially normal, the price and the permission to keep a good thing going, plus a real path to getting it covered. The Cycler needs the thing the trials never built, a protocol for coming off and holding the result: the maintenance dosing, the microdosing, the support that turns “I stopped” into something other than “I regained.” The Longevity Optimizer needs the data and the framing to run this as healthspan infrastructure rather than a weight drug. The Locked Out needs the next molecule, the gentler tolerability, and the cheap, steady access that finally opens the door.
That is five distinct products, five distinct journeys, sitting underneath a category everyone is still describing with a singularity. I am not certain which of these cohorts ends up largest, or whether the lines hold exactly where I have drawn them. Nobody can be, because the cheap-pill population only started arriving a few months ago. But I am confident the useful work is here: not predicting whether GLP-1s are good or bad for snack stocks, but reading what the drug becomes to real people, earlier and more precisely than anyone else, and building for whichever version of them you choose to serve. Get the people right and the behavior, the preferences, and the wallet all follow. Get them wrong and you are shorting snacks in 2023, technically correct about the mechanism and still on the wrong side of the trade, because you bet on one behavior when there were always five.
Affordable enough to never really stop is the gravitational pull of this whole story. But not everyone falls into the same orbit, and the work is in knowing exactly who falls where
This is my hypothesis. I would love to hear yours.